CLINICAL_TRIALS
trial_result
· 2021-07-22
Clinical Trial Update: Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients [Phase 1]
Summary
Phase I dose-escalation study of BI 836909 monotherapy in last-line multiple myeloma completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2021-07-22